Fujifilm Holdings Corporation

Overview

Fujifilm Holdings Corporation (TSE: 4901) is a Japanese multinational conglomerate headquartered in Tokyo, Japan, with significant operations in healthcare and pharmaceuticals. The company's pharmaceutical division, Fujifilm Toyama Chemical Co., Ltd., has been developing novel therapeutics for central nervous system disorders, including the sigma-1 receptor agonist T-817MA for Alzheimer's and Parkinson's disease[@fujifilm2021].

Fujifilm has leveraged its expertise in chemical synthesis and drug development to advance a pipeline of CNS-targeting compounds, with T-817MA representing their lead program in the neurodegeneration space.

Sigma-1 Receptor Agonist Program

T-817MA

T-817MA is a selective sigma-1 receptor agonist developed by Fujifilm Toyama Chemical for the treatment of neurodegenerative diseases:

| Attribute | Value |
|-----------|-------|
| Target | Sigma-1 receptor (SIGMAR1) |
| Mechanism | Sigma-1 receptor agonist, neuroprotection |
| Indication | Alzheimer's disease, Parkinson's disease |
| Development Stage | Phase II (Japan) |
| Route | Oral |

Mechanism of Action

T-817MA exerts neuroprotective effects through sigma-1 receptor activation:

Overview

Fujifilm Holdings Corporation (TSE: 4901) is a Japanese multinational conglomerate headquartered in Tokyo, Japan, with significant operations in healthcare and pharmaceuticals. The company's pharmaceutical division, Fujifilm Toyama Chemical Co., Ltd., has been developing novel therapeutics for central nervous system disorders, including the sigma-1 receptor agonist T-817MA for Alzheimer's and Parkinson's disease[@fujifilm2021].

Fujifilm has leveraged its expertise in chemical synthesis and drug development to advance a pipeline of CNS-targeting compounds, with T-817MA representing their lead program in the neurodegeneration space.

Sigma-1 Receptor Agonist Program

T-817MA

T-817MA is a selective sigma-1 receptor agonist developed by Fujifilm Toyama Chemical for the treatment of neurodegenerative diseases:

| Attribute | Value |
|-----------|-------|
| Target | Sigma-1 receptor (SIGMAR1) |
| Mechanism | Sigma-1 receptor agonist, neuroprotection |
| Indication | Alzheimer's disease, Parkinson's disease |
| Development Stage | Phase II (Japan) |
| Route | Oral |

Mechanism of Action

T-817MA exerts neuroprotective effects through sigma-1 receptor activation:

Preclinical Evidence

Studies in preclinical models have demonstrated[@toyama2020]:

• Protection against amyloid-beta toxicity in neuronal cultures
• Improved cognitive function in Alzheimer's disease mouse models
• Neuroprotective effects in dopaminergic neuron models
• Reduced oxidative stress and apoptosis
• Improved mitochondrial function

Clinical Development

| Trial | Phase | Indication | Status | Notes |
|-------|-------|------------|--------|-------|
| NCT02052271 | Phase I | Alzheimer's disease | Completed | Safety and tolerability established |
| NCT02873390 | Phase II | Alzheimer's disease | Completed | Japan |
| TBD | Phase II | Parkinson's disease | Planning | Based on preclinical PD data |

Competitive Position

T-817MA represents Fujifilm's entry into the sigma-1 receptor agonist field:

| Factor | T-817MA | Blarcamesine (Anavex) | Notes |
|--------|---------|----------------------|-------|
| Selectivity | High sigma-1 | Sigma-1 + muscarinic | Different mechanism |
| Development stage | Phase II (Japan) | Phase II/III (global) | Blarcamesine ahead |
| Geography | Japan-focused | Global | Different markets |
| Formulation | Oral | Oral | Similar delivery |

Pipeline Overview

| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| T-817MA | Sigma-1R | Alzheimer's/Parkinson's | Phase II |
| T-2558 | Undisclosed | CNS | Preclinical |
| T-3889 | Undisclosed | Rare disease | Research |

Corporate Information

Headquarters: Tokyo, Japan

Founded: 1934 (as Fujifilm Corporation)

Ticker: TSE 4901

Healthcare Division: Fujifilm Toyama Chemical Co., Ltd.

Key Focus Areas:

• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)
• Oncology
• Vaccines

Strategic Context

Fujifilm's entry into sigma-1 receptor agonists reflects their broader strategy to expand in CNS therapeutics:

Cross-References

• [Sigma-1 Receptor Agonists for Parkinson's Disease](/mechanisms/sigma1-receptor-agonists-parkinsons)
• [Sigma-1 Receptor Agonists for Neurodegenerative Diseases](/therapeutics/sigma1-receptor-agonists-neurodegeneration)
• [SIGMAR1 Gene](/genes/sigmar1)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

References